Immunotherapy

"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

Descriptor ID	D007167
MeSH Number(s)	E02.095.465.425
Concept/Terms	Immunotherapy Immunotherapy Immunotherapies

Below are MeSH descriptors whose meaning is more general than "Immunotherapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Biological Therapy [E02.095]
Immunomodulation [E02.095.465]
Immunotherapy [E02.095.465.425]

Below are MeSH descriptors whose meaning is related to "Immunotherapy".

Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.

Bar chart showing 181 publications over 30 distinct years, with a maximum of 25 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	3	3
1997	1	1	2
1998	1	1	2
1999	0	1	1
2000	0	1	1
2001	0	1	1
2002	1	1	2
2003	3	3	6
2004	0	2	2
2005	2	1	3
2006	2	6	8
2007	0	4	4
2008	0	1	1
2009	1	1	2
2010	0	2	2
2011	2	1	3
2012	0	3	3
2013	2	1	3
2014	5	2	7
2015	2	0	2
2016	4	1	5
2017	9	3	12
2018	10	5	15
2019	12	2	14
2020	10	15	25
2021	2	9	11
2022	2	9	11
2023	2	13	15
2024	4	6	10
2025	2	3	5

Below are the most recent publications written about "Immunotherapy" by people in Profiles.

Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.

View in: PubMed
Carr AS, Vonberg FW, Koay S, Young K, Shaw H, Olsson-Brown A, Willis M. Neurological complications of immune checkpoint inhibitors: a practical guide. Pract Neurol. 2025 Mar 14; 25(2):116-126.

View in: PubMed
Elyaman W, Stern LJ, Jiang N, Dressman D, Bradley P, Klatzmann D, Bradshaw EM, Farber DL, Kent SC, Chizari S, Funk K, Devanand D, Thakur KT, Raj T, Dalahmah OA, Sarkis RA, Weiner HL, Shneider NA, Przedborski S. Exploring the role of T?cells in Alzheimer's and other neurodegenerative diseases: Emerging therapeutic insights from the T Cells in the Brain symposium. Alzheimers Dement. 2025 Feb; 21(2):e14548.

View in: PubMed
Varanasi SK, Chen D, Liu Y, Johnson MA, Miller CM, Ganguly S, Lande K, LaPorta MA, Hoffmann FA, Mann TH, Teneche MG, Casillas E, Mangalhara KC, Mathew V, Sun M, Jensen IJ, Farsakoglu Y, Chen T, Parisi B, Deota S, Havas A, Lee J, Chung HK, Schietinger A, Panda S, Williams AE, Farber DL, Dhar D, Adams PD, Feng GS, Shadel GS, Sundrud MS, Kaech SM. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science. 2025 01 10; 387(6730):192-201.

View in: PubMed
Malode A, Makwana B, Patel V, Khadke S, Parikh A, Bagga A, Dani S, Ganatra S. Cardiotoxicity and peri-operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review. Anaesthesia. 2025 Feb; 80 Suppl 2:25-37.

View in: PubMed
Zhou L, Ma B, Ruscetti M. Cellular senescence offers distinct immunological vulnerabilities in cancer. Trends Cancer. 2025 Apr; 11(4):334-350.

View in: PubMed
Manole S, Nguyen DH, Min JJ, Zhou S, Forbes N. Setting "cold" tumors on fire: Cancer therapy with live tumor-targeting bacteria. Med. 2025 Jan 10; 6(1):100549.

View in: PubMed
Mittal K, Joshi M. Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward. Med. 2024 Dec 13; 5(12):1449-1451.

View in: PubMed
Sari G, Dhatchinamoorthy K, Orellano-Ariza L, Ferreira LM, Brehm MA, Rock K. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas. J Exp Clin Cancer Res. 2024 Oct 02; 43(1):276.

View in: PubMed
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 Aug 28; 16(762):eadj9366.

View in: PubMed

People

Explore

Similar Concepts

Top Journals